Anzeige
Mehr »
Login
Samstag, 17.04.2021 Börsentäglich über 12.000 News von 660 internationalen Medien
Breaking News! Taat Lifestyle meldet riesige Kauforder!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0YD8Q ISIN: US58933Y1055 Ticker-Symbol: 6MK 
Tradegate
16.04.21
21:48 Uhr
64,73 Euro
+0,70
+1,09 %
1-Jahres-Chart
MERCK & CO INC Chart 1 Jahr
5-Tage-Chart
MERCK & CO INC 5-Tage-Chart
RealtimeGeldBriefZeit
64,4864,8116.04.
64,5064,7916.04.

Aktuelle News zur MERCK & CO Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrMerck Keeps Plowing On3
FrMerck (MRK) Stops MK-7110 Development, Focuses on Molnupiravir2
FrIs Merck Stock A Buy As It Teams Up To Produce J&J's Covid Vaccine?6
MERCK & CO Aktie jetzt für 0€ handeln
FrPharma Stock Roundup: JNJ's COVID-19 Vaccine Woes, MRK Ends COVID-19 Drug Development6
FrMerck's Covid-19 drug R&D falls short twice in treating hospitalized patients6
DoMerck hurt by another setback in its battle against COVID-192
DoMerck & Co halts development of potential COVID-19 drug MK-71101
DoMerck, partner halt covid-19 treatment trial for hospitalized patients2
DoMerck ends studies for experimental MK-7110 drug to fight severe COVID-191
DoMerck cans one COVID-19 drug, scraps a clinical trial of another2
DoMerck, Ridgeback Biotherapeutics Update Covid Drug Development Program188KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) and Ridgeback Biotherapeutics announced that the companies plan to proceed with the phase 3 portion of phase 2/3 study of investigational drug Molnupiravir...
► Artikel lesen
DoMerck To Discontinue Development Of COVID-19 Drug 'MK-7110'193KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) said Thursday that it has decided to discontinue development of MK-7110, formerly known as CD24Fc, for the treatment of hospitalized patients with COVID-19...
► Artikel lesen
DoThe Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split12
DoMerck & Co stoppt Studie mit Covid-19-Mittel bei Krankenhauspatienten208DJ Merck & Co stoppt Studie mit Covid-19-Mittel bei Krankenhauspatienten Von Jared S. Hopkins und Betsy McKay NEW YORK (Dow Jones)--Merck & Co. sowie sein Partner Ridgeback Biotherapeutics...
► Artikel lesen
DoMerck ends development of Covid drug it acquired from OncoImmune2
DoMerck advances molnupiravir into Phase 3 MOVe-OUT study in COVID-192
DoMerck scraps two treatments for hospitalized COVID-19 patients, will focus on antiviral for non-hospitalized patients3
DoMerck & Co: Debt Overview4
DoMerck scraps their $425M Covid-19 drug in latest pandemic setback1
DoMerck nixes development plans for MK-7110 in COVID-191
Seite:  Weiter >>
790 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
7,2,38